Treatment of LBBB Patients Meeting Sgarbossa Criteria for AMI
Understanding Sgarbossa Criteria in LBBB
- The American College of Emergency Physicians recommends that patients with LBBB who meet Sgarbossa criteria indicating acute myocardial infarction should receive immediate fibrinolytic therapy if PCI cannot be performed within 90 minutes of first medical contact, with a Level B recommendation for patients with symptom onset less than 3 hours 1, 2
- The Sgarbossa criteria have a sensitivity of 73% and specificity of 92% for ST-segment elevation ≥1 mm and concordant with the QRS complex, a sensitivity of 25% and specificity of 96% for ST-segment depression ≥1 mm in leads V1-V3, and a sensitivity of 19% and specificity of 82% for ST-segment elevation ≥5 mm and discordant with the QRS complex 2
Reperfusion Strategy Algorithm
- The American Heart Association recommends identifying patients with suspected AMI and LBBB meeting any Sgarbossa criteria, and determining the time from symptom onset to guide reperfusion therapy 2, 3, 4
- For patients with symptom onset less than 3 hours, the American College of Cardiology recommends administering fibrinolytic therapy if PCI cannot be performed within 90 minutes, with a Level B recommendation 1, 4
- For patients with symptom onset between 3-6 hours and high-risk, the American College of Cardiology recommends administering fibrinolytic therapy if PCI cannot be performed within 90 minutes, with a Level C recommendation 4
Important Clinical Considerations
- The presence of any Sgarbossa criteria has high specificity (>90%) and positive predictive value for AMI, making these patients appropriate candidates for reperfusion therapy, according to the American College of Emergency Physicians 2
- Patients with LBBB have historically received lower rates of reperfusion therapy despite having higher mortality rates compared to patients without BBB, as reported by the American Heart Association 6, 7
Follow-up Management
- The American College of Cardiology recommends continuing standard post-MI care including antiplatelet therapy, anticoagulation, and cardiac monitoring after initiating reperfusion therapy 5